Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, Alfonso-Alvarado C, Cabrera-Placeres M, Castro-Basart N, Duncan-Roberts Y, Carballo-Treto TI, Soto-Matos J, Izquierdo-Toledo Y, Vázquez-Blomquist D, García-Iglesias E, Bello-Rivero I. García-Vega Y, et al. BMC Pharmacol Toxicol. 2012 Dec 28;13:20. doi: 10.1186/2050-6511-13-20. BMC Pharmacol Toxicol. 2012. PMID: 23272809 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I, Hernández-González I, Díaz-Machado A, González-Delgado CA, Pérez-Rodríguez S, García-Vega Y, Campos-Mojena R, Tuero-Iglesias ÁD, Valenzuela-Silva CM, Cruz-Ramírez A, Martín-Trujillo A, Santana-Milián H, López-Saura PA, Bello-Rivero I; CIGB-128-A Study Group. García-García I, et al. BMC Pharmacol Toxicol. 2016 Dec 7;17(1):58. doi: 10.1186/s40360-016-0103-8. BMC Pharmacol Toxicol. 2016. PMID: 27923408 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group. García-García I, et al. BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15. BMC Pharmacol. 2010. PMID: 21092287 Free PMC article. Clinical Trial.
Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
Hernández-Bernal F, García-García I, González-Delgado CA, Valenzuela-Silva C, Soto-Hernández R, Ducongé J, Cervantes-Llano M, Blanco-Garcés E, Rodríguez V, García-Vega Y, Bello-Rivero I, Olivera-Ruano L, López-Saura P. Hernández-Bernal F, et al. Biopharm Drug Dispos. 2005 May;26(4):151-9. doi: 10.1002/bdd.445. Biopharm Drug Dispos. 2005. PMID: 15799006 Clinical Trial.
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.
Milanés-Virelles MT, García-García I, Santos-Herrera Y, Valdés-Quintana M, Valenzuela-Silva CM, Jiménez-Madrigal G, Ramos-Gómez TI, Bello-Rivero I, Fernández-Olivera N, Sánchez-de la Osa RB, Rodríguez-Acosta C, González-Méndez L, Martínez-Sánchez G, López-Saura PA; MACGAM Study Group. Milanés-Virelles MT, et al. BMC Infect Dis. 2008 Feb 11;8:17. doi: 10.1186/1471-2334-8-17. BMC Infect Dis. 2008. PMID: 18267006 Free PMC article. Clinical Trial.
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.
Santos-Morales O, Díaz-Machado A, Jiménez-Rodríguez D, Pomares-Iturralde Y, Festary-Casanovas T, González-Delgado CA, Pérez-Rodríguez S, Alfonso-Muñoz E, Viada-González C, Piedra-Sierra P, García-García I, Amaro-González D; NeuroEPO Study Group; García-Rodríguez JC, Sosa-Testé I, Lagarto-Parra A, Barrero-Viera L, David-Baldo M, Tamayo-Rodríguez M, Rivero-Vázquez I, González-Gamiz G, Martín-Trujillo A, Rodríguez-Fernández Y, Ledo-de la Luz AA, Álvarez-Delgado M, Howland-Álvarez I, Cruz-Gómez Y. Santos-Morales O, et al. BMC Neurol. 2017 Jul 4;17(1):129. doi: 10.1186/s12883-017-0908-0. BMC Neurol. 2017. PMID: 28676085 Free PMC article. Clinical Trial.
Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA; Bioequivalence Study of Erythropoietin Group. Pérez-Oliva JF, et al. BMC Nephrol. 2005 May 23;6:5. doi: 10.1186/1471-2369-6-5. BMC Nephrol. 2005. PMID: 15910687 Free PMC article. Clinical Trial.
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.
Rodriguez-Labrada R, Ortega-Sanchez R, Hernández Casaña P, Santos Morales O, Padrón-Estupiñan MDC, Batista-Nuñez M, Jiménez Rodríguez D, Canales-Ochoa N, Peña Acosta A, Medrano Montero J, Labrada Aguilera PE, Estupiñán Rodriguez A, Vazquez-Mojena Y, Almaguer Gotay D, Aymed-García J, García-García I, Torres Vega R, Viada González C, Valenzuela Silva CM, Silva Ricardo Y, Columbié Ximelis J, Tribin Rivero K, Valle Cabrera R, García-Rodriguez JC, Crombet Ramos T, Amaro-González D, Rodriguez-Obaya T, Velázquez-Pérez L. Rodriguez-Labrada R, et al. Mov Disord. 2022 Jul;37(7):1516-1525. doi: 10.1002/mds.29045. Epub 2022 May 23. Mov Disord. 2022. PMID: 35607776 Clinical Trial.
252 results